David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 20,738 shares at $43.01 ($892K) on 2025-10-15, disclosed to the SEC on 2025-10-15.
Scheduled sale ($892k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.01 | 10,369 | $446K | 50.0% |
| 2 | $43.01 | 10,369 | $446K | 50.0% |
| Total | $43.01 avg | 20,738 | $892K | 100% |
| Filing → |
| MLYS | SELL | 2026-07-15 | $557K | — | Filing → |
| MLYS | SELL | 2026-07-10 | $66K | — | Filing → |
| MLYS | SELL | 2026-06-17 | $350K | — | Filing → |